EB1|CAS 42951-68-8|DC Chemicals

Cas No.:	42951-68-8
Chemical Name:	4,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3-amine
Synonyms:	4,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3-amine;EB1;CS-0459580;DA-05906;4,6-diphenyl-2H-pyrazolo[3,4-b]pyridin-3-amine;42951-68-8;SCHEMBL13329661;AKOS016024870;HY-146805;GLXC-25582;3-amino-4,6-diphenyl-pyrazolo[3,4-b]pyridine;BDBM50605099;Oprea1_313960;CHEMBL5189796
SMILES:	C1=CC=C(C=C1)C2=CC(=NC3=NNC(=C23)N)C4=CC=CC=C4
Formula:	C₁₈H₁₄N₄
M.Wt:	286.33056306839
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC72816	EB1	EB1 is the inhibitor of kinases MNK with IC50s of 0.69 μM (MNK1) and 9.4 μM (MNK2). EB1 selectively inhibits the growth of cancer cells, but not normal cells. EB1 also increases cell apoptosis and suppresses eIF4E phosphorylation.
DC70393	ETC-168	ETC-168 (ETC168) is a potent, selective MNK kinase inhibitor with biochemical IC50 of 23 and 43 nM against MNK1 and MNK2, respectively.ETC-168 acts as a MNK2-biased, dual-MNK inhibitor in cells.ETC-168 induced dose-dependent growth suppression and inhibited 50% of cell viability at 5 uM in LPS141 and MESSA, ETC-168 treatment elicited a consistent increase of cells in G0/G1 phase among LPS141, LP6, and MESSA cells in a dose-dependent manner. ETC-168 decreased cells of S and G2/M phases, while no significant induction of sub-G1 cells.Inhibition of MNK1/2 by ETC-168 elevated the expression of MNK1/2 at both transcript and protein levels in soft tissue sarcoma (STS) cells.ETC-168 effectively suppressed both p-4E and cell viability in MESSA cells, but not CGP57380 and eFT508.ETC-168 suppresseed phosphorylation of ribosomal protein S6 (RPS6) in sensitive STS cell, decreased expression of E2F1, FOXM1, and WEE1.Inhibition of MCL1 via S63845 synergizes with ETC-168 against STS cells.
DC9755	eFT508(Tomivosertib)	Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.